Figure 5.

Inhibition of GSK3β reverses hyperactivity in TNiK^−/− mice. A–C, Locomotor activity was assessed in an open field chamber and total distance moved measured (A). Representative tracks of wt (A, left) and TNiK^−/− (A, right) mice in the open field. GSK3β inhibition on locomotor activity (B) was assessed by placing TNiK^−/−and wt mice in an activity chamber for an initial period of 30 min, then mice were injected (indicated by arrow) with either vehicle or a GSK3β inhibitor (SB 216763; 10 mg/kg body weight, i.p.) and monitored for a further period of 30 min starting 10 min after injection. Sensitivity to GSK3β (C) was calculated as a ratio of change in locomotor activity between administration of vehicle and GSK3β inhibitor. *p < 0.05; **p < 0.01; ***p < 0.005; a = TNiK^−/− vehicle versus wt vehicle; b = TNiK^−/− vehicle versus TNiK^−/− GSK3β inhibitor.